004720 팜젠사이언스
기본 정보
- 섹터: KOSPI:제약
- 시가총액: 661억원 (2026-06-30 기준)
- 첫 등장: — (마커 미등장)
- 태그: 매크로/바이오헬스 · 매크로/소비미디어 · 전문의약품 · 소화기치료제 · 바이오신약 · 건강기능식품
- 네이버 금융: 🔗
기업개요
- 동사는 1966년 설립되어 소화기 치료제 중심의 제약사업과 건강기능식품 중심의 헬스케어사업을 영위하고 있음.
- 경기도 화성시에 본점과 생산시설을 두고, 6개 도매지점, 9개 전국 지점, 글로벌 R&D센터를 운영하며 전문의약품, 일반의약품 및 신약개발에 힘쓰고 있음.
- 주요 제품으로는 에소맥스정(궤양치료제), 바르디핀정(고혈압치료제), 리바틴정, 크바젯정(고지혈증 치료제), 세파클러(항생제), 네프리스엔(신장질환치료제) 등이 있음.
출처: 네이버증권 종목분석 (WiseReport)
일자별 등장 (최신 위, 누적)
| 일자 | 전일 종가 | 종가 | 등락률 | 시간외 | vol | 색깔 | smart | 외 | 연 | 금투 | 투 | 개 | 그외 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | 3,245 | 3,270 | 🔴 +0.77% | — | ×0.4 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-08-06 | 3,245 | 3,245 | ⚪ +0.00% | — | ×0.3 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.2 | +0.0 |
| 2026-08-05 | 3,325 | 3,245 | 🔵 -2.41% | — | ×0.8 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.1 | +0.1 |
| 2026-08-04 | 3,330 | 3,325 | 🔵 -0.15% | — | ×0.7 | ⚫ 그외 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | +0.0 | +0.1 |
| 2026-08-03 | 3,250 | 3,330 | 🔴 +2.46% | — | ×0.7 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-31 | 3,150 | 3,250 | 🔴 +3.17% | — | ×0.6 | ⚫ 그외 | -0.1억 | -0.1 | +0.0 | -0.0 | +0.0 | +0.0 | +0.1 |
| 2026-07-30 | 3,190 | 3,150 | 🔵 -1.25% | — | ×0.5 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-29 | 3,275 | 3,190 | 🔵 -2.60% | — | ×1.4 | ⚫ 그외 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.6 | +0.5 |
| 2026-07-28 | 3,450 | 3,275 | 🔵 -5.07% | — | ×1.0 | ⚫ 그외 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.3 | +0.2 |
| 2026-07-27 | 3,440 | 3,450 | 🔴 +0.29% | — | ×0.3 | 🔻 개인 | -0.1억 | -0.1 | +0.0 | -0.0 | +0.0 | +0.1 | +0.0 |
| 2026-07-24 | 3,475 | 3,440 | 🔵 -1.01% | — | ×0.7 | 🟢 외인 | +0.3억 | +0.3 | +0.0 | +0.0 | +0.0 | -0.4 | +0.2 |
| 2026-07-23 | 3,380 | 3,475 | 🔴 +2.81% | — | ×0.6 | ⚫ 그외 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | -0.4 | +0.4 |
| 2026-07-22 | 3,480 | 3,380 | 🔵 -2.87% | — | ×0.7 | ⚫ 그외 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.1 | +0.1 |
| 2026-07-21 | 3,325 | 3,480 | 🔴 +4.66% | — | ×1.2 | 🟢 외인 | +0.4억 | +0.4 | +0.0 | +0.0 | +0.0 | -0.6 | +0.2 |
| 2026-07-20 | 3,400 | 3,325 | 🔵 -2.21% | — | ×1.2 | ⚫ 그외 | -0.5억 | -0.5 | +0.0 | +0.0 | +0.0 | -0.4 | +0.8 |
| 2026-07-16 | 3,360 | 3,400 | 🔴 +1.19% | — | ×1.5 | ⚫ 그외 | +0.4억 | +0.4 | +0.0 | +0.0 | +0.0 | -0.9 | +0.5 |
| 2026-07-15 | 3,045 | 3,360 | 🔴 +10.34% | — | ×1.6 | 🟢 외인 | +0.6억 | +0.6 | +0.0 | +0.0 | +0.0 | -0.7 | +0.1 |
| 2026-07-14 | 2,965 | 3,045 | 🔴 +2.70% | — | ×4.3 | ⚫ 그외 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -1.1 | +1.0 |
| 2026-07-13 | 3,050 | 2,965 | 🔵 -2.79% | — | ×0.7 | ⚫ 그외 | -0.0억 | -0.0 | +0.0 | +0.0 | +0.0 | -0.2 | +0.2 |
| 2026-07-10 | 3,070 | 3,050 | 🔵 -0.65% | — | ×0.5 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.2 | +0.0 |
| 2026-07-09 | 3,200 | 3,070 | 🔵 -4.06% | — | ×0.3 | 🔻 개인 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | +0.2 | +0.0 |
| 2026-07-08 | 3,115 | 3,200 | 🔴 +2.73% | — | ×0.9 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.2 | +0.1 |
| 2026-07-07 | 3,165 | 3,115 | 🔵 -1.58% | — | ×0.4 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | -0.0 |
| 2026-07-06 | 3,190 | 3,165 | 🔵 -0.78% | — | ×0.7 | ⚫ 그외 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | -0.3 | +0.4 |
| 2026-07-03 | 3,115 | 3,190 | 🔴 +2.41% | — | ×1.0 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | -0.0 | +0.0 | -0.2 | +0.0 |
| 2026-07-02 | 3,050 | 3,115 | 🔴 +2.13% | — | ×0.8 | ⚫ 그외 | +0.0억 | +0.0 | +0.0 | +0.0 | +0.0 | -0.1 | +0.1 |
| 2026-07-01 | 2,920 | 3,050 | 🔴 +4.45% | — | ×0.8 | ⚫ 그외 | -0.2억 | -0.2 | +0.0 | +0.0 | +0.0 | -0.3 | +0.6 |
| 2026-06-30 | 3,030 | 2,920 | 🔵 -3.63% | — | ×0.3 | 🟢 외인 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.0 |
| 2026-06-29 | 2,870 | 3,030 | 🔴 +5.57% | — | ×0.4 | 🟢 외인 | +0.2억 | +0.2 | +0.0 | +0.0 | +0.0 | -0.2 | +0.0 |
| 2026-06-26 | 2,925 | 2,870 | 🔵 -1.88% | — | ×0.6 | ⚫ 그외 | -0.1억 | -0.1 | +0.0 | +0.0 | +0.0 | -0.1 | +0.2 |
| 2026-06-25 | 2,820 | 2,925 | 🔴 +3.72% | — | ×0.6 | ⚫ 그외 | +0.1억 | +0.1 | +0.0 | +0.0 | +0.0 | -0.3 | +0.2 |
일자별 사유 (최신 위)
2026-07-15
- 사유: 제약 테마 강세 편승
- 섹터 컨텍스트: KOSPI:제약 (smart +554억)
- 매크로 원인: HLB 리보세라닙 FDA 제조 리스크 해소 기대에 그룹주 무더기 상한가, 미프진 허가 검토·항암신약 모멘텀 가세 (보통)